A prespecified pooled secondary analysis of the STEP-HFpEF trials found semaglutide improved symptoms, weight, and exercise capacity consistently across baseline C-reactive protein strata and lowered CRP regardless of weight loss. PICO summary and expert commentary.
Author: Hormone Insight Editorial Team
Read More
A secondary analysis of the pooled STEP-HFpEF trials found semaglutide improved heart-failure symptoms more in obesity-related HFpEF patients with a history of atrial fibrillation than in those without. PICO summary and expert commentary.
An echocardiography substudy of the STEP-HFpEF Program found once-weekly semaglutide 2.4 mg attenuated left atrial and right ventricular remodeling versus placebo over 52 weeks. PICO summary and expert commentary.
A phase 2b randomized trial of the GLP-1/glucagon dual agonist cotadutide in type 2 diabetes and CKD, with dose-dependent reductions in albuminuria at week 14. PICO summary and expert commentary.
A single-centre RCT (n=180) testing an integrated cloud data platform with dietary management and education videos against routine care in type 2 diabetes, with HbA1c lower at 12 weeks. PICO summary and expert commentary.
A post hoc analysis of the SUSTAIN 6 trial reports that once-weekly semaglutide was associated with lower odds of developing diabetic kidney disease in adults with type 2 diabetes who had no kidney disease at baseline. PICO summary and expert commentary.
A post-hoc pooled analysis of four semaglutide trials found a lower risk of cardiovascular death or worsening heart failure in patients with HFpEF, though cardiovascular death alone was not reduced. PICO summary and expert commentary.
A prespecified secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials examining whether semaglutide 2.4 mg benefits in obesity-related HFpEF differ by sex. PICO summary and expert commentary.
A 12-week pilot RCT comparing an 800 kcal/day very-low calorie diet, semaglutide, and their combination in 30 adults with type 2 diabetes. PICO summary and expert commentary.
A prespecified analysis of the SELECT trial examining whether semaglutide 2.4 mg reduces cardiovascular and heart failure outcomes in patients with obesity and prevalent heart failure. PICO summary and expert commentary.